When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Before Congress adjourned for Christmas, congressional leadership had set ambitious goals to counter the Chinese Communist ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...

The transaction – announced on Christmas Eve – comes after WuXi AppTec has been thrust into the US political spotlight as a ...

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...

The future of the BIOSECURE Act was made more uncertain over the weekend after senators left the legislation out of a pivotal defence budget bill. The omission means the act, which intends to ...

The US House earlier this year resoundingly voted in favor of the blacklist legislation, dubbed the Biosecure Act, and a bipartisan group in the Senate supported the measure as well. But senior ...

2024 was eventful in the life sciences space – and key trends are expected to continue in the new year. Below, we outline key areas to watch in 2025. In recent years, several trends have heightened ...

The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s ...

The Biosecure Act was left out of a key US defence bill that passed in the House last week, in a major win for Chinese CDMOs. Shares in WuXi AppTec (Shanghai, China) opened 10.5% higher on ...